<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="SARS-CoV-2 treatment http://orcid.org/0000-0002-6380-7114BuonaguroLuigil.buonaguro@istitutotumori.na.it1BuonaguroFranco M.2[1], grid.417893.00000 0001 0807 2568Laboratory of Innovative" exact="Immunological" post="Models, Istituto Nazionale per lo Studio e la Cura"/>
 <result pre="IRCCS, [2], grid.417893.00000 0001 0807 2568Laboratory of Molecular Biology and" exact="Viral" post="Oncology, Istituto Nazionale per lo Studio e la Cura"/>
 <result pre="containment of the SARS-CoV-2 pandemic and limit the progression of" exact="disease" post="to potentially deadly COVID19. Funding http://dx.doi.org/10.13039/100010677H2020 Health 643638BuonaguroLuigi A"/>
 <result pre="human coronavirus named SARS-CoV-2 was identified in several cases of" exact="acute" post="respiratory syndrome in Wuhan, China in December 2019 [1,"/>
 <result pre="coronavirus named SARS-CoV-2 was identified in several cases of acute" exact="respiratory" post="syndrome in Wuhan, China in December 2019 [1, 2]."/>
 <result pre="named SARS-CoV-2 was identified in several cases of acute respiratory" exact="syndrome" post="in Wuhan, China in December 2019 [1, 2]. The"/>
 <result pre="and inhalation transmission of droplets) and transmission by contact with" exact="mucosa" post="[3]. The viral load of SARS-CoV-2 in saliva can"/>
 <result pre="of droplets) and transmission by contact with mucosa [3]. The" exact="viral" post="load of SARS-CoV-2 in saliva can exceed 1â€‰Ã—â€‰108 viral"/>
 <result pre="The viral load of SARS-CoV-2 in saliva can exceed 1â€‰Ã—â€‰108" exact="viral" post="copies per milliliter [4] both in symptomatic and asymptomatic"/>
 <result pre="can exceed 1â€‰Ã—â€‰108 viral copies per milliliter [4] both in" exact="symptomatic" post="and asymptomatic positive subjects [5]. Consequently, it is necessary"/>
 <result pre="subjects [5]. Consequently, it is necessary to reduce or block" exact="viral" post="replication to avoid the progression of the disease towards"/>
 <result pre="or block viral replication to avoid the progression of the" exact="disease" post="towards the full-blown and potentially lethal form (COVID19), but"/>
 <result pre="and potentially lethal form (COVID19), but also to reduce the" exact="viral" post="titer and viral shedding through saliva, in symptomatic and"/>
 <result pre="form (COVID19), but also to reduce the viral titer and" exact="viral" post="shedding through saliva, in symptomatic and asymptomatic infected individuals."/>
 <result pre="reduce the viral titer and viral shedding through saliva, in" exact="symptomatic" post="and asymptomatic infected individuals. Specific drugs for SARS-CoV-2 are"/>
 <result pre="specific to each RNA virus, regardless the polarity of the" exact="viral" post="RNA genome [10, 11]. Nevertheless, significant differences are identified"/>
 <result pre="should take into consideration the molecular basis of the genomic" exact="viral" post="RNA. SARS-CoV-2 is a positive-sense RNA virus. The only"/>
 <result pre="RdRp is available and approved world-wide for clinical use, is" exact="hepatitis C" post="virus (HCV). In the specific, Sofosbuvir (SovaldiÂ®; EpclusaÂ® by"/>
 <result pre="Gilead) is a direct antiviral agent (DAA) that inhibits the" exact="hepatitis C" post="NS5B RdRp protein [13]. Interestingly, it has been already"/>
 <result pre="humans for other two different positive-sense RNA viruses, namely Yellow" exact="Fever" post="and Hepatitis A virus [14, 15]. The alignment of"/>
 <result pre="other two different positive-sense RNA viruses, namely Yellow Fever and" exact="Hepatitis" post="A virus [14, 15]. The alignment of RdRp sequences"/>
 <result pre="from negative-sense RNA viruses, namely Ebola, Influenza, Rabies and Vesicular" exact="Stomatitis" post="viruses [16]. The structure modeling shows that RdRp of"/>
 <result pre="RdRp protein, as antiviral in the treatment of the SARS-CoV-2" exact="infection" post="has an extremely high potentiality of success, as recently"/>
 <result pre="of the SARS-CoV-2 RdRp in the target cells of the" exact="respiratory" post="tract. In conclusion, the data here reported indicate the"/>
 <result pre="the long-lasting use in patients for treating and eradicating HCV" exact="chronic" post="infection provides also the full knowledge of its safety"/>
 <result pre="long-lasting use in patients for treating and eradicating HCV chronic" exact="infection" post="provides also the full knowledge of its safety profile"/>
 <result pre="N/A Consent for publication N/A Competing interests Authors declare the" exact="absence of" post="any competing interest. References References 1.HuiDSAzharIMadaniTANtoumiFKockRDarOet al.The continuing 2019-nCoV"/>
 <result pre="Travel Med. 2020;27(2):taaa011. 10.1093/jtm/taaa011. PMID: 31985790. 3.LuCWLiuXFJiaZF2019-nCoV transmission through the" exact="ocular" post="surface must not be ignoredLancet2020395e3910.1016/S0140-6736(20)30313-532035510 4.To KK, Tsang OT,"/>
 <result pre="2020;ciaa149. 10.1093/cid/ciaa149. Online ahead of print. 5.RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCet al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med202038297097110.1056/NEJMc200146832003551"/>
 <result pre="AC, Graham RL, Sheahan TP, Lu X et al.: Coronavirus" exact="Susceptibility to" post="the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral"/>
 <result pre="Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the" exact="Viral" post="Polymerase and the Proofreading Exoribonuclease. mBio 2018;9(2):e00221-18. 10.1128/mBio.00221-18. 9.TaleviABelleraCLChallenges"/>
 <result pre="left behindInt J Antimicrob Agents20195375576010.1016/j.ijantimicag.2018.12.01030605721 14.MendesEAPilgerDRBSantos NastriACSMaltaFMPascoalinoBDSCarneiro D'AlbuquerqueLAet al.Sofosbuvir inhibits" exact="yellow fever" post="virus in vitro and in patients with acute liver"/>
 <result pre="inhibits yellow fever virus in vitro and in patients with" exact="acute" post="liver failureAnn Hepatol20191881682410.1016/j.aohep.2019.09.00131594756 15.JiangWMuhammadFMaPLiuXLongGSofosbuvir inhibits hepatitis a virus replication"/>
 <result pre="and in patients with acute liver failureAnn Hepatol20191881682410.1016/j.aohep.2019.09.00131594756 15.JiangWMuhammadFMaPLiuXLongGSofosbuvir inhibits" exact="hepatitis" post="a virus replication in vitro assessed by a cell-based"/>
 <result pre="inhibitors, repurposing against COVID-19Life Sci202024811747710.1016/j.lfs.2020.11747732119961 18.BoettlerTNewsomePNMondelliMUMaticicMCorderoECornbergMet al.Care of patients with" exact="liver disease" post="during the COVID-19 pandemic: EASL-ESCMID position paperJHEP Rep2020210011310.1016/j.jhepr.2020.10011332289115"/>
 <result pre="repurposing against COVID-19Life Sci202024811747710.1016/j.lfs.2020.11747732119961 18.BoettlerTNewsomePNMondelliMUMaticicMCorderoECornbergMet al.Care of patients with liver" exact="disease" post="during the COVID-19 pandemic: EASL-ESCMID position paperJHEP Rep2020210011310.1016/j.jhepr.2020.10011332289115"/>
</results>
